Meda’s MP29-02 (Dymista) was found to be well tolerated and effective in three clinical trials conducted in patients with chronic allergic or non-allergic rhinitis.

MP29-02 is an intranasal formulation of azelastine hydrochloride and fluticasone propionate, and is under review by the US Food and Drug Administration (FDA) for the treatment of seasonal allergic rhinitis (SAR).

In the randomised open-label active-controlled parallel-group first study, 612 patients were treated with either MP29-02 one spray per nostril twice daily or fluticasone propionate two sprays per nostril once daily.

During the one-year period, the study evaluated safety and tolerability, and also assessed efficacy by measuring the 12-hour reflective total nasal symptom score (rTNSS) scored once daily.

The first study demonstrated that continuous treatment with MP29-02 was well tolerated and showed greater relief from nasal symptoms than fluticasone-treated patients over the one-year study period.

Lead author of the first study William Berger said: "These data show support for the safety and efficacy of this novel nasal spray formulation, especially for patients who have persistent symptoms of seasonal allergic rhinitis that may require longer-term treatment."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised double-blind placebo and active controlled two week pivotal trials, MP4002 and MP4004, conducted in more than 1600 patients with moderate-to-severe SAR evaluated MP29-02 for the treatment of ocular symptoms associated with SAR, a key secondary endpoint in the MP29-02 clinical development programme.

The primary endpoint of the trials was change from baseline in the 12-hour reflective total nasal symptom score (rTNSS), and the secondary endpoint was the 12-hour reflective total ocular symptom score (rTOSS), including itchy eyes, watery eyes, and eye redness.

In the second and third studies, patients with SAR demonstrated considerable relief from nasal symptoms and also improved TOSS compared to placebo over a two-week study period.

Meda CEO Anders Lönner said: "These data provide additional important evidence that Dymista can offer significant benefits to patients and may play a critical role in the future treatment of patients with SAR."